Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 300 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $130.12, for a total transaction of $39,036.00. Following the completion of the sale, the chief marketing officer now owns 271,621 shares of the company’s stock, valued at approximately $35,343,324.52. The transaction was disclosed in a filing with the SEC, which is available through this link.

Jane Huang also recently made the following trade(s):

  • On Monday, April 8th, Jane Huang sold 14,130 shares of Beigene stock. The stock was sold at an average price of $142.77, for a total transaction of $2,017,340.10.
  • On Thursday, March 7th, Jane Huang sold 71 shares of Beigene stock. The stock was sold at an average price of $140.50, for a total transaction of $9,975.50.
  • On Monday, March 11th, Jane Huang sold 2,636 shares of Beigene stock. The stock was sold at an average price of $130.28, for a total transaction of $343,418.08.

NASDAQ:BGNE traded down $0.91 on Wednesday, reaching $129.72. 239,844 shares of the company’s stock were exchanged, compared to its average volume of 340,811. The company has a quick ratio of 7.47, a current ratio of 7.52 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $7.76 billion, a PE ratio of -10.68 and a beta of 1.07. Beigene Ltd has a 52 week low of $105.19 and a 52 week high of $220.10.

Beigene (NASDAQ:BGNE) last issued its earnings results on Thursday, May 9th. The company reported ($2.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.15) by $0.34. The firm had revenue of $77.83 million during the quarter, compared to analyst estimates of $55.79 million. Beigene had a negative net margin of 302.58% and a negative return on equity of 44.75%. The company’s quarterly revenue was up 139.2% on a year-over-year basis. During the same quarter last year, the business earned ($2.03) earnings per share. Analysts anticipate that Beigene Ltd will post -13.16 earnings per share for the current fiscal year.

Several research firms recently weighed in on BGNE. Bank of America began coverage on shares of Beigene in a research report on Friday, March 15th. They set a “buy” rating and a $200.00 price target for the company. BidaskClub lowered shares of Beigene from a “buy” rating to a “hold” rating in a research report on Friday, January 25th. Piper Jaffray Companies reduced their price target on shares of Beigene to $170.00 and set an “overweight” rating for the company in a research report on Thursday, February 28th. Maxim Group set a $170.00 price target on shares of Beigene and gave the company a “buy” rating in a research report on Thursday, February 28th. Finally, ValuEngine lowered shares of Beigene from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 15th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Beigene presently has an average rating of “Buy” and an average target price of $182.34.

A number of large investors have recently modified their holdings of BGNE. Hillhouse Capital Advisors Ltd. bought a new position in Beigene during the fourth quarter worth about $622,467,000. BlackRock Inc. boosted its position in Beigene by 294.9% during the fourth quarter. BlackRock Inc. now owns 1,877,110 shares of the company’s stock worth $263,281,000 after purchasing an additional 1,401,773 shares during the period. Northern Trust Corp boosted its position in Beigene by 22,043.2% during the fourth quarter. Northern Trust Corp now owns 566,423 shares of the company’s stock worth $79,446,000 after purchasing an additional 563,865 shares during the period. Norges Bank bought a new position in Beigene during the fourth quarter worth about $47,799,000. Finally, Fiera Capital Corp boosted its position in Beigene by 3,554.4% during the fourth quarter. Fiera Capital Corp now owns 215,464 shares of the company’s stock worth $30,221,000 after purchasing an additional 209,568 shares during the period. Hedge funds and other institutional investors own 79.66% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Beigene Ltd (BGNE) CMO Sells 300 Shares of Stock” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://theolympiareport.com/2019/05/22/insider-selling-beigene-ltd-bgne-cmo-sells-300-shares-of-stock.html.

Beigene Company Profile

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Recommended Story: Why does a company issue an IPO?

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.